Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + MM-141 + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
MM-141 | Istiratumab | HER3 (ERBB3) Antibody 23 IGF1R Antibody 8 | Istiratumab (MM-141) is a monoclonal antibody, which binds to human epidermal growth factor receptor B3 (ERBB3) and the human insulin-like growth factor-1 receptor (IGF-1R), blocking ligand binding and preventing activation of PI3K/AKT signaling (PMID: 24282274, PMID: 31912800). | |
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01733004 | Phase I | Everolimus + MM-141 MM-141 Gemcitabine + MM-141 + Nab-paclitaxel | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | Completed | USA | FRA | 0 |